K N Roy Chengappa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11564416/publications.pdf

Version: 2024-02-01

47 papers

2,443 citations

279798 23 h-index 243625 44 g-index

48 all docs

48 docs citations

48 times ranked

2340 citing authors

#	Article	IF	CITATIONS
1	Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. Archives of General Psychiatry, 2002, 59, 62.	12.3	410
2	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser <i>v.</i> mood stabiliser alone. British Journal of Psychiatry, 2004, 184, 337-345.	2.8	288
3	Clozapine Reduces Severe Self-Mutilation and Aggression in Psychotic Patients With Borderline Personality Disorder. Journal of Clinical Psychiatry, 1999, 60, 477-484.	2.2	117
4	The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtype. Bipolar Disorders, 2004, 6, 314-318.	1.9	115
5	Bipolar Disorder and the Metabolic Syndrome. CNS Drugs, 2008, 22, 655-669.	5.9	115
6	Dosage and Administration Issues of Antipsychotic Agents (and Adjunctive Medicines) in the Acute Stabilization of Psychoses. CNS Spectrums, 2004, 9, 6-10.	1.2	112
7	Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review. Clinical Therapeutics, 2002, 24, 1576-1584.	2.5	108
8	Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disorders, 2009, 11, 34-44.	1.9	98
9	Randomized Placebo-Controlled Adjunctive Study of an Extract of <i>Withania somnifera </i> for Cognitive Dysfunction in Bipolar Disorder. Journal of Clinical Psychiatry, 2013, 74, 1076-1083.	2.2	89
10	Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. European Psychiatry, 2001, 16, 186-190.	0.2	78
11	Rates of response, euthymia and remission in two placeboâ€controlled olanzapine trials for bipolar mania. Bipolar Disorders, 2003, 5, 1-5.	1.9	74
12	Varenicline for Smoking Cessation in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, 765-772.	2.2	74
13	A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. Schizophrenia Research, 2012, 142, 145-152.	2.0	69
14	Anticholinergic Differences Among Patients Receiving Standard Clinical Doses of Olanzapine or Clozapine. Journal of Clinical Psychopharmacology, 2000, 20, 311-316.	1.4	68
15	Adjunctive Topiramate Therapy in Patients Receiving a Mood Stabilizer for Bipolar I Disorder. Journal of Clinical Psychiatry, 2006, 67, 1698-1706.	2.2	64
16	A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clinical Therapeutics, 2003, 25, 530-541.	2.5	56
17	The Off-Label Use of Clozapine in Adolescents with Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 57-63.	1.3	50
18	Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia. Journal of Clinical Psychiatry, 2018, 79, .	2.2	44

#	Article	IF	CITATIONS
19	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disorders, 2005, 7, 68-76.	1.9	43
20	Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disorders, 2008, 10, 566-579.	1.9	40
21	Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic. General Hospital Psychiatry, 2012, 34, 660-664.	2.4	35
22	Weight gain and metabolic issues of medicines used for bipolar disorder. Current Psychiatry Reports, 2007, 9, 521-528.	4.5	27
23	Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions. Schizophrenia Research, 2020, 222, 532-533.	2.0	26
24	Hypomania: hype <i>or</i> mania?. Bipolar Disorders, 2010, 12, 758-763.	1.9	25
25	Group teletherapy for firstâ€episode psychosis: Piloting its integration with coordinated specialty care during the COVIDâ€19 pandemic. Psychology and Psychotherapy: Theory, Research and Practice, 2021, 94, 382-389.	2.5	22
26	A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study. Canadian Journal of Psychiatry, 2003, 48, 187-194.	1.9	21
27	Treatment of bipolar mania with atypical antipsychotics. Expert Review of Neurotherapeutics, 2004, 4, S17-S25.	2.8	21
28	Subtle changes in thyroid indices during a placebo-controlled study of an extract of Withania somnifera in persons with bipolar disorder. Journal of Ayurveda and Integrative Medicine, 2014, 5, 241.	1.7	21
29	Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. Addiction, 2013, 108, 1962-1968.	3.3	19
30	Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia. Neuropsychopharmacology, 2018, 43, 1334-1342.	5.4	17
31	The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 437-440.	4.8	16
32	Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. Nicotine and Tobacco Research, 2015, 18, ntv085.	2.6	16
33	Ensuring care for clozapine-treated schizophrenia patients during the COVID-19 pandemic. Schizophrenia Research, 2020, 222, 499-500.	2.0	14
34	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. Journal of Clinical Psychopharmacology, 2008, 28, 247-248.	1.4	12
35	<i>Atypical mood stabilizers</i> : a new role for neuroleptics?. Bipolar Disorders, 2011, 13, 583-586.	1.9	12
36	Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatric Quarterly, 2020, 91, 137-145.	2.1	8

#	Article	IF	CITATIONS
37	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. Asian Journal of Psychiatry, 2009, 2, 106-111.	2.0	4
38	ECT for a pregnant patient with bipolar disorder in the COVIDâ€19 Era: A clinical conundrum. Bipolar Disorders, 2021, 23, 524-527.	1.9	3
39	From Office-Based Treatment to Telehealth: Comparing Clinical Outcomes and Patient Participation in a Psychiatric Intensive Outpatient Program with a Large Transdiagnostic Sample. Telemedicine Journal and E-Health, 2021, , .	2.8	3
40	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. Journal of Clinical Psychopharmacology, 2009, 29, 193-194.	1.4	2
41	Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia. Schizophrenia Research, 2022, 243, 170-177.	2.0	2
42	Long term outcomes in persons with bipolar disorder—Developing versus developed countries. Asian Journal of Psychiatry, 2010, 3, 49.	2.0	1
43	All aboard: the Journal's journey to broader contentâ€ment. Bipolar Disorders, 2017, 19, 412-413.	1.9	1
44	Editorial. Bipolar Disorders, 2010, 12, 757-757.	1.9	0
45	The Potential Utility of Ashwagandha for Improving Cognitive Dysfunction in Persons with Bipolar or Other Neurocognitive Disorders., 2017,, 345-371.		O
46	A cognitive perspective on mood. Bipolar Disorders, 2018, 20, 180-180.	1.9	0
47	Efectos a largo plazo del topiramato sobre la inestabilidad del estado de ánimo bipolar, el cambio de peso y el control glucémico: una serie clÃnica. European Psychiatry (Ed Española), 2001, 8, 361-365.	0.0	0